Cargando…
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
BACKGROUND: Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, complete remission has not been achieved and the molecular basis of HCC resistance to sorafenib remains largely unknown. Previous studies have shown that fibroblast gr...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223586/ https://www.ncbi.nlm.nih.gov/pubmed/28069043 http://dx.doi.org/10.1186/s13046-016-0478-9 |